Laurus Labs Ltd logo

Laurus Labs Ltd

LAURUSLABS NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
₹97,477 Cr
Volatility
Moderate
P/E Ratio
89.62
EBITDA
₹1,833 Cr
Return on Equity
16.38%
Debt to Equity
0.48
Book Value
₹98.09
EPS
₹2.75
52W High
₹1,870.8
52W Low
₹823.1

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Laurus Labs Ltd insights

49 extracted metrics + investor summaries across FY06–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 19.0%

Weaknesses

4
  • Stock is trading at 18.4 times its book value
  • The company has delivered a poor sales growth of 7.19% over past five years.
  • Company has a low return on equity of 10.1% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
22.01% ↗
Net Income Growth
151.10% ↗
Cash Flow Change
169.84% ↗
ROE
112.73% ↗
ROCE
62.83% ↗
EBITDA Margin (Avg.)
32.87% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk high

Laurus Labs trades at a market cap of ₹99,139 Cr with a PE of 91.2x and PB of 18.8x, reflecting elevated valuations despite modest 5-year sales CAGR of 7%. The stock has surged 114% in the past year, driven by a sharp TTM profit recovery of 115%, though longer-term profit CAGR over 5 years remains negative at -2%.

Bull Case 7
  • TTM profit growth of 115% signals a strong earnings recovery, suggesting the trough in profitability may be behind the company
  • TTM sales growth of 23% marks a significant acceleration compared to the 3-year sales CAGR of just 4%, indicating improving demand momentum
  • Last year ROE of 18% is well above the 3-year average of 10%, showing a meaningful improvement in capital efficiency
  • 10-year compounded profit growth of 21% demonstrates the company's long-term ability to scale earnings over full business cycles
  • 10-year sales CAGR of 14% reflects a credible track record of sustained revenue expansion in the pharmaceutical API and formulations space
  • 5-year ROE average of 15% and 10-year ROE of 17% indicate historically strong return generation capability that may be reverting to mean
  • Consistent dividend payout ratio of 19.0% demonstrates management's commitment to shareholder returns even during lean periods
Bear Case 8
  • PE ratio of 91.2x is extremely elevated for a pharma company, leaving little margin of safety if earnings growth disappoints
  • Stock trading at 18.8x book value implies a massive premium that requires sustained high growth to justify current price levels
  • 5-year compounded profit growth of -2% indicates the company actually destroyed earnings over a half-decade period despite revenue increases
  • 5-year sales CAGR of only 7.19% is below industry peers and barely above inflation, reflecting sluggish top-line expansion
  • 3-year ROE of just 10.1% is below typical cost of equity, suggesting the company has struggled to generate adequate returns on capital in recent years
  • Stock price surging 114% in one year while 3-year profit CAGR is only 4% suggests valuation may be running far ahead of fundamental earnings power
  • Potential capitalization of interest costs may be flattering reported profits and understating the true operating expense burden
  • Dividend yield of just 0.11% offers negligible income cushion for investors at current elevated price levels

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 19h ago
Positives 3
  • Q1 profit surges 125% YoY Jul 24

    Consolidated net profit more than doubled to ₹362 crore (vs ₹162 crore YoY), beating analyst estimates of ₹270 crore. Revenue rose 29% to ₹2,026 crore with EBITDA margins expanding to 31.8% from 24.35%.

  • CDMO targeting 50% revenue by FY30 Jul 25

    Management confident CDMO segment will reach 50% of total revenue by FY30. ROCE currently at 19% with a stated aim to reach 23% over time.

  • Broad capex push FY27-FY28 Jul 24

    Laurus Labs is scaling capital expenditure across human health, animal health, peptides, gene therapy, and antibody drug conjugates over FY27 and FY28, signaling commitment to high-value biotechnology platforms.

Neutral 4
  • ₹16.95 Cr block trade on NSE Jul 29

    Approximately 95,224 shares traded at ₹1,780.10 per share in a block deal worth ₹16.95 crore, indicating institutional interest at current price levels.

  • NCLT hearing set Sep 10, 2026 Jul 25

    NCLT Amravati scheduled next hearing for the composite scheme involving demerger of LSPL Unit-1 into Sriam Labs and amalgamation of the remainder with parent company.

  • Independent Director retires Jul 24

    Dr. Rajesh Koshy Chandy retired as Independent Director effective July 26, 2026, after completing his second term.

  • Q1 FY27 conference call released Jul 24

    Audio recording of Q1 FY27 results conference call made available per SEBI LODR Regulations 30 and 46.

TL;DR: Laurus Labs delivered a standout Q1 FY27 with 125% profit growth, 29% revenue expansion, and margin improvement to 31.8%, driven by strong CDMO momentum. Management is doubling down with broad capex across pharma and biotech platforms while targeting 50% CDMO revenue share by FY30. No material headwinds emerged this cycle. The trend is clearly improving, with execution on the CDMO pivot being the key monitorable going forward.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,182
1,224
1,195
1,440
1,195
1,224
1,415
1,720
1,570
1,653
1,778
1,812
2,026
Expenses
1,015
1,037
1,014
1,198
1,024
1,045
1,130
1,300
1,187
1,250
1,298
1,299
1,388
Operating Profit
167
188
181
241
171
178
285
421
382
403
480
512
638
OPM %
14%
15%
15%
17%
14%
15%
20%
24%
24%
24%
27%
28%
32%
Other Income
4
2
2
19
3
5
9
59
10
27
6
12
9
Interest
39
42
51
50
49
53
58
56
52
40
39
40
42
Depreciation
91
93
98
102
106
108
106
110
117
120
121
122
124
PBT
41
54
35
107
18
23
131
312
224
270
327
361
481
Tax %
30%
27%
27%
30%
34%
22%
31%
25%
28%
28%
22%
22%
25%
Net Profit
27
37
23
75
13
20
93
233
162
194
252
282
362
EPS in Rs
0.46
0.69
0.43
1.4
0.23
0.37
1.71
4.33
3.02
3.61
4.66
5.17
6.8
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,327
1,778
1,905
2,056
2,292
2,832
4,814
4,936
6,041
5,041
5,554
6,813
7,270
Expenses
1,126
1,415
1,497
1,642
1,935
2,266
3,262
3,512
4,448
4,261
4,499
5,028
5,236
Operating Profit
200
362
408
414
357
565
1,552
1,424
1,592
779
1,055
1,785
2,034
OPM %
15%
20%
21%
20%
16%
20%
32%
29%
26%
15%
19%
26%
28%
Other Income
34
4
32
29
15
5
23
14
6
24
75
47
54
Interest
106
111
100
80
88
90
68
102
165
183
216
171
161
Depreciation
62
86
106
125
164
187
205
251
324
385
430
480
487
PBT
67
169
234
237
120
294
1,301
1,084
1,109
236
484
1,182
1,439
Tax %
-2%
21%
19%
29%
22%
13%
24%
23%
28%
29%
27%
25%
—
Net Profit
68
134
190
168
94
255
984
832
793
162
358
890
1,091
EPS in Rs
8.81
16.97
3.6
3.16
1.76
4.77
18.33
15.4
14.67
2.98
6.64
16.46
20.24
Div. Payout %
0%
2%
8%
9%
17%
10%
11%
13%
14%
27%
18%
12%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
106
106
106
107
107
107
108
108
108
108
Reserves
640
774
1,225
1,377
1,452
1,663
2,490
3,244
3,930
4,003
4,365
5,192
Borrowings
888
1,094
842
980
1,036
1,079
1,482
1,777
2,015
2,577
2,764
2,518
Other Liabilities
345
339
481
554
737
901
1,671
1,840
1,608
1,699
2,099
2,693
Total Liabilities
1,888
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
10,511
Fixed Assets
801
1,021
1,230
1,481
1,629
1,726
2,171
2,652
3,409
3,890
4,123
4,371
CWIP
110
70
143
163
110
67
362
813
551
423
458
773
Investments
7
7
3
3
3
3
3
31
50
124
233
309
Other Assets
970
1,126
1,277
1,369
1,589
1,953
3,214
3,472
3,651
3,950
4,521
5,058
Total Assets
1,888
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
10,511
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-65
182
332
342
298
347
733
911
994
666
602
1,624
Investing
-397
-312
-289
-384
-253
-221
-941
-914
-997
-822
-680
-1,086
Financing
486
103
-54
42
-45
-128
255
30
-27
250
39
-525
Net Cash Flow
24
-27
-10
1
0
-1
47
27
-30
93
-39
13
Free Cash Flow
-447
-144
55
-49
44
125
49
34
6
-10
61
560
CFO/OP
-24
59
94
98
91
68
62
77
80
99
70
107
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
78
91
109
101
113
102
99
100
96
120
132
115
Inventory Days
210
176
186
201
201
234
266
293
222
277
285
317
Days Payable
102
90
96
107
144
159
199
146
94
158
141
170
Cash Conversion Cycle
186
178
199
195
170
177
166
247
224
240
276
263
Working Capital Days
0
19
3
-11
6
15
43
43
59
42
43
58
ROCE %
14%
16%
16%
14%
8%
14%
40%
26%
23%
7%
9%
18%

Shareholding Pattern

As of Jun 2026
FIIs 28.00%
Promoters 27.47%
Public 20.49%
DIIs 13.74%
Others 10.30%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
27.45%
27.30%
27.30%
27.27%
27.27%
27.27%
27.27%
27.20%
27.20%
27.20%
27.20%
27.19%
27.19%
27.18%
27.18%
27.62%
27.62%
27.59%
27.59%
27.49%
27.49%
27.47%
FIIs
0.00%
0.04%
0.04%
0.02%
0.02%
0.02%
0.00%
0.02%
0.02%
0.00%
0.00%
0.00%
25.97%
25.67%
26.08%
25.56%
25.52%
25.70%
26.16%
26.52%
25.82%
28.00%
DIIs
2.06%
2.40%
2.11%
2.77%
3.51%
4.77%
8.98%
9.51%
9.74%
10.14%
10.71%
10.77%
11.77%
13.56%
13.05%
12.74%
11.77%
11.94%
11.73%
12.43%
13.97%
13.74%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
34.17%
34.18%
32.91%
32.87%
31.15%
28.42%
27.96%
28.95%
28.49%
28.26%
26.49%
25.01%
23.95%
22.68%
22.67%
22.72%
23.65%
23.12%
23.33%
22.64%
21.24%
20.49%
Others
36.32%
36.07%
37.65%
37.08%
38.05%
39.53%
35.80%
34.32%
34.55%
34.39%
35.60%
37.03%
11.12%
10.91%
11.03%
11.36%
11.44%
11.65%
11.18%
10.92%
11.47%
10.30%
No. of Shareholders
2,35,836
2,99,257
3,94,053
4,67,419
4,27,465
4,07,186
3,90,695
4,23,931
4,18,615
4,17,977
4,02,640
3,82,880
3,56,830
3,24,059
3,09,063
2,92,214
2,92,905
2,80,223
2,83,678
2,80,756
2,92,281
2,91,653

Documents

Frequently Asked Questions about Laurus Labs Ltd

What does Laurus Labs Ltd do?
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They a...
Where is Laurus Labs Ltd (LAURUSLABS) listed?
Laurus Labs Ltd is listed on the Indian stock exchanges. It is listed on NSE: LAURUSLABS and BSE: 540222. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Laurus Labs Ltd belong to?
Laurus Labs Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Laurus Labs Ltd?
Laurus Labs Ltd has a market capitalisation of approximately ₹97476.50 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Laurus Labs Ltd?
The Price-to-Earnings (PE) ratio of Laurus Labs Ltd is 89.62. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Laurus Labs Ltd?
Over the past 52 weeks, Laurus Labs Ltd has traded between a low of ₹823.1 and a high of ₹1,870.8. This range helps investors understand the stock's price volatility and recent trading levels.
Does Laurus Labs Ltd pay dividends?
Yes, Laurus Labs Ltd has a dividend yield of 0.11%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Laurus Labs Ltd?
Laurus Labs Ltd has a Return on Equity (ROE) of 16.38%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Laurus Labs Ltd on Tapetide?
On Tapetide, you can view Laurus Labs Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Website lauruslabs.com
CEO Dr. Satyanarayana Chava M.Sc., Ph.D.
Employees 6,167
Listed 2016-12-19
Face Value ₹ 2
Issued Size 53,98,56,582

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List